Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999408 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning
A NA study of Alopecia and Hair Thinning, sponsored by Recens Medical.
- Active
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06999408: Active NA study of Alopecia and Hair Thinning, sponsored by Recens Medical.
NCT06999408 is a NA study of Alopecia and Hair Thinning that is active but no longer recruiting, run by Recens Medical. The registered enrollment target is 15 participants, below the 124-participant average among 13 other Alopecia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999408, a NA study of Alopecia and Hair Thinning, is active but no longer recruiting, sponsored by Recens Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is testing a new approach to help improve hair thinning using a combination of cosmetic treatments. The purpose of the study is to learn whether applying exosomes to the scalp, along with microneedling and a precision cooling device called TargetCool™. This study aims to determine whether this combination approach offers synergistic benefits for individuals with hair thinning. Exosomes are tiny particles that come from stem cells and contain growth factors and other nutrients. They are being studied for their potential to help regenerate skin and hair. TargetCool™ is an FDA-cleared device that uses precision cooling to reduce inflammation and improve comfort. Microneedling is a common, minimally invasive procedure that uses small needles to stimulate the skin and help absorb topical products more effectively. The study will include healthy men (ages 18 to 70) and women (ages approximately 45 to 70) who are not of childbearing potential. A total of 9 to 15 participants will be randomly placed into one of three groups: Group 1: Exosomes with TargetCool™ Group 2: Microneedling followed by exosomes and TargetCool™ Group 3: Microneedling followed by exosomes only Participants will receive four treatments over 9 weeks. Each visit may include microneedling, TargetCool™ treatment, and exosome application depending on group assignment. A small tattoo will be placed on the scalp to help capture consistent photographs, and a special imaging system (Canfield HairMetrix®) will be used to measure hair changes. Participants will return for follow-up visits at 3 and 6 months after the final treatment. The results will help determine whether this combination of cosmetic treatments is safe and beneficial for people experiencing hair thinning.
Primary Outcome
Terminal hair is defined as coarse hair, short or long, found on the scalp with minimum cross-sectional diameter of 40 micrometers. This is calculated by the Canfield HairMetrix System.
Conditions Studied
Interventions
- DEVICE Scalp tattoo
- DEVICE Canfield HairMetrix®
- DEVICE TargetCool
- DEVICE Microneedle-facilitated lidocaine application
Study Locations (1)
New York
- Marc Avram MD - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT06999408 still lists
NCT06999408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 124-participant average among 13 other Alopecia trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Alopecia appearing as the primary indexed condition, and to 4 interventions - of which Scalp tattoo is the first listed.
NCT06999408 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06999408 about?
NCT06999408 is a clinical study titled "Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning". This clinical trial is testing a new approach to help improve hair thinning using a combination of cosmetic treatments. The purpose of the study is to learn whether applying exosomes to the scalp, along with microneedling and a precision cooling device called TargetCool™. This study aims to determin...
What is the current status of trial NCT06999408?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-09-16. Estimated completion is 2026-05.
What conditions does trial NCT06999408 study?
This clinical trial studies the following conditions: Alopecia, Hair Thinning, Hair Diseases.
What interventions are being tested in trial NCT06999408?
The interventions under investigation include: Scalp tattoo (DEVICE), Canfield HairMetrix® (DEVICE), TargetCool (DEVICE), Microneedle-facilitated lidocaine application (DEVICE).
Who is sponsoring clinical trial NCT06999408?
This trial is sponsored by Recens Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999408 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06999408's enrollment target sits among peer trials
15 13th of 13 higher than 1 of 13 other Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
RECRUITING · NA
-
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
RECRUITING · NA
-
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
RECRUITING · NA
-
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
RECRUITING · NA
-
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI